Supplemental material
Expert Opinion on Drug Safety
Volume 20, 2021 - Issue 3
Original Research
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Tomohiro Itoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0002-6456-2825View further author information
https://orcid.org/0000-0002-6456-2825View further author information, Yusuke Naitoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japanhttps://orcid.org/0000-0001-8033-6708View further author information
https://orcid.org/0000-0001-8033-6708View further author information, , , & Related Research Data
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Source:
Taylor & Francis
Linking provided by
